Willing to Win

Christian Rados

Biotech Leaders Against All Odds Biotech leaders, founders and executives are warriors chasing cures against impossible odds. Their journeys are not only about science, but about belief, resilience, and leadership. Willing to Win is the podcast where these stories are told — the late nights, the rejections, the doubts, and the unshakable conviction that keeps them going. Each episode gives listeners an intimate look into the emotional “why” behind biotech leaders, offering inspiration, connection, and lessons in leadership and perseverance that apply far beyond biotech.

Episodes

  1. An IPO Is Just The Beginning | The Real Fight Starts When You Go Public

    6D AGO

    An IPO Is Just The Beginning | The Real Fight Starts When You Go Public

    Willing To Win: Biotech Leaders Against All Odds Episode 3 An IPO Is Just the Beginning | What No One Tells You About Running a Public Company In this episode of Willing To Win, Christian Rados sits down with Oliver Schacht to unpack a truth most founders only discover the hard way: The IPO is not the victory. It is the moment the real pressure begins. Oliver Schacht is a PhD-trained molecular biologist turned biotech CEO who has led companies through the intensity of public markets in Europe and the United States. He has raised capital across borders, navigated regulatory storms, faced investor scrutiny, and operated under the full transparency of listed companies. But this conversation is not about ringing the bell. It begins with a sentence that changes the tone immediately: “I had to cancel my honeymoon for the IPO.” Not said with pride. Said with clarity. Because markets do not reward milestones. They reward performance. Every quarter. Every signal. Every word. Oliver speaks openly about what happens after the headlines fade. The volatility. The scrutiny. The loneliness. The weight of knowing that a single sentence can move markets. This episode explores what leadership demands when you operate in full visibility. When market cycles turn against you. When uncertainty becomes constant and conviction becomes your anchor. Rather than focusing on deal mechanics, this conversation goes deeper. Into the mindset required to endure public pressure. Into the discipline of staying calm when stock prices swing. Into the resilience required to carry thousands of shareholders while protecting your team. Topics discussed include: Why an IPO marks the start of the hardest chapter The psychological shift from private founder to public CEO The difference between European and U.S. capital markets Leading when every word has consequences The loneliness of accountability at scale What it takes to stay in the game when markets turn hostile Willing To Win is about biotech leadership when the odds are real. It is about decisions made without certainty, responsibility carried without applause, and the conviction required to move forward when the stakes are public. Episode 3 guest Oliver Schacht Oliver Schacht is a biotech executive and former public company CEO with deep experience across science, capital markets, and executive leadership. He has co-founded and led publicly traded life science companies, executed IPOs, raised significant international financing, and operated at the intersection of innovation and investor scrutiny. Today, he serves as CEO of Life Science Nord. His career reflects what it truly means to lead under pressure, where ambition meets accountability and resilience defines survival.

    47 min
  2. Feeling Out Of Place | The Story Behind Edwin Moses - And How Insecurity Fueled Optimism

    FEB 5

    Feeling Out Of Place | The Story Behind Edwin Moses - And How Insecurity Fueled Optimism

    Willing To Win: Biotech Leaders Against All Odds Episode 2 Feeling Out Of Place | The Story Behind Edwin Moses - And How Insecurity Fueled Optimism In this episode of Willing to Win, Christian Rados sits down with Edwin Moses, one of the most accomplished and quietly influential leaders in European biotech, to explore the inner journey behind a lifetime of exceptional outcomes. Edwin Moses has played a defining role across decades of biotech leadership. He served as Chairman of Ablynx, which was acquired by Sanofi for €3.9 billion, and later as Chairman of Dark Blue Therapeutics, acquired by Amgen for $840 million. These are rare wins. But this conversation is not about celebrating deals or numbers. Instead, it goes back to the beginning. Long before boardrooms, transactions, or public recognition, Edwin was a child who felt deeply out of place. Insecure. Visibly different. Learning early that attention could feel unsafe and that staying unnoticed sometimes felt like the best option. Rather than disappearing, those early experiences stayed with him. Over time, they shaped a mindset grounded in humility, gratitude, and a quiet optimism. Not the loud optimism of certainty or bravado, but a steady inner belief that if you work hard, stay patient, and keep going, things will be okay. In this conversation, Edwin reflects on how insecurity does not always lead to fear or withdrawal. In some cases, it becomes fuel. Fuel for persistence. Fuel for resilience. Fuel for an optimism that endures even when confidence is missing and outcomes are uncertain. This episode explores what leadership looks like when ego is absent and responsibility is heavy. It looks at how calm decision making is formed under pressure, how humility can coexist with ambition, and how repeated success does not erase insecurity but can coexist with it in a healthy, grounded way. Rather than focusing on deal mechanics, this conversation focuses on the human side of leadership. The inner forces that keep leaders moving forward when logic says stop, when the stakes are enormous, and when clarity only emerges after action is taken. Topics discussed include: Childhood insecurity and the lasting impact of early experiences Feeling out of place and why it does not have to define who you become How insecurity can quietly fuel optimism and perseverance Gratitude, grit, and the discipline of simply doing the work Leading without ego while carrying responsibility for billions Staying grounded and calm during hostile bids and high pressure moments Willing to Win is a podcast about biotech leadership against all odds. It focuses on real decisions, inner battles, and the mindset that keeps leaders moving forward when certainty is impossible and the stakes are real. Episode 2 guest:Edwin MosesEdwin Moses has more than 30 years of Board level experience as a serial entrepreneur and value creator in over 20 European life science companies. As CEO, he built, Oxford Asymmetry International plc and Ablynx NV, led successful IPOs on the LSE, EuroNext and NASDAQ, and raised over USD500 million in equity and debt financing.  Edwin was responsible for the sales of both companies generating values of £316 million and USD4.8 billion respectively.  Edwin is currently also Chairman of Avantium NV, LabGenius Ltd and NanoSyrinx Ltd.

    42 min

About

Biotech Leaders Against All Odds Biotech leaders, founders and executives are warriors chasing cures against impossible odds. Their journeys are not only about science, but about belief, resilience, and leadership. Willing to Win is the podcast where these stories are told — the late nights, the rejections, the doubts, and the unshakable conviction that keeps them going. Each episode gives listeners an intimate look into the emotional “why” behind biotech leaders, offering inspiration, connection, and lessons in leadership and perseverance that apply far beyond biotech.